SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

Read our quick round-up of the LEAD trials of the daily injectable GLP-1 receptor agonist liraglutide in people with type 2 diabetes.

We round up the medications currently approved for treating type 2 diabetes in children and adolescents and look at what agents are coming through clinical trials.

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

Combination therapy with three commonly used medications has achieved similar levels of pain relief for people with diabetic peripheral neuropathic pain in the randomized OPTION-DM trial.

Read our Hot Topic Review for a rapid update on the successes and failures of immunotherapies in people with or at high risk for type 1 diabetes.

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

There were only 276 exposures to other diabetes medications, so the researchers did not investigate these further.

Data from primary care suggest that use of sodium-glucose cotransporter2 inhibitors, and possibly glucagon-like peptide-1 receptor agonists, may reduce the risk for cardiovascular disease events in people with type 2 diabetes without previous events.

There is much less evidence for use of other glucose-lowering agents; although sulfonylureas and metformin are often used, they may not be sufficient to control hyperglycemia in many patients.

Tirzepatide improves glucose control more than semaglutide in people with type 2 diabetes by improving beta-cell function as well as boosting insulin sensitivity and reducing glucagon secretion, shows a randomized trial.

People with type 2 diabetes who have mental health conditions are just as likely as those who do not to achieve their blood glucose targets, report researchers.

Analysis of older people living in Denmark shows that doctors are increasingly deprescribing medications given solely to reduce blood glucose as people with type 2 diabetes near their end of life.

Structured monitoring of blood glucose improves its control regardless of the device used, although continuous glucose monitoring is better than self-monitored blood glucose for reducing hypoglycemia, shows a randomized trial.

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

Three trials ( ELIXA , EXSCEL , and AMPLITUDE-O ) involved medications with an exendin-4 structural basis, whereas the medications used in the other five trials ( LEADER , SUSTAIN-6 , Harmony Outcomes , REWIND , and PIONEER 6 ) are based on human GLP-1.